Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: Study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)

Biliary tract cancer (BTC) is a relatively rare but highly aggressive malignancy. However, there is currently no satisfactory second-line regimen for patients without specific genetic mutations. Nanoparticle albumin–bound paclitaxel, also known as nab-paclitaxel (Abraxane, Bristol Myers Squibb), has shown activity in patients with BTC.